Charles River Laboratories International (CRL) Expected to Announce Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect Charles River Laboratories International to post earnings of $2.06 per share and revenue of $942.34 million for the quarter. Charles River Laboratories International has set its FY 2025 guidance at 9.100-9.600 EPS and its FY25 guidance at $9.10-$9.60 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company posted $2.46 EPS. The company's revenue was down 1.1% compared to the same quarter last year. On average, analysts expect Charles River Laboratories International to post $9 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Charles River Laboratories International Trading Up 2.0 %

NYSE:CRL opened at $117.35 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $254.15. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 782.33, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The stock has a fifty day simple moving average of $144.83 and a 200 day simple moving average of $170.07.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Barclays dropped their target price on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. Finally, Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $182.00.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.